Yasin ARGIMAK, Osman TEMİZÖZ, ALPTEKİN TOSUN, Bilge ÇAKIR

Mangafodipir trisodyum ile pankreas malign kitlelerinin değerlendirilmesi

Amaç: Organ spesifik ajan olan mangafodipir trisodyum (Mn-DPDP) kullanılarak yapılan manyetik rezonans görüntülemenin pankreas malign kitlelerinin incelenmesinde tanısal etkinliğini incelemek. Hastalar ve Yöntemler: Abdominal ultrasonografi ve bilgisayarlı tomografi bulguları ile pankreas tümörü düşünülen 17 hastanın (7 kadın, 10 erkek; ort. yaş 63.2±12; dağılım 36-80) manyetik rezonans görüntüleri, T1A SE, yağ baskılı T1A SE ve T1A GRE sekanslarının kullanımı ile sinyal-gürültü (S/N) ve kontrast-gürültü (C/N) oranları açısından Mn-DPDP uygulaması öncesi ve sonrası incelendi. Bulgular: Kontrast öncesi ve sonrası incelemelerde normal pankreasın S/N oranlarında artış T1A SE sekansta ortalama %22.81, yağ baskılı T1A SE sekansında %32.88 ve T1A GRE sekansında %20 olarak bulundu. Normal pankreas dokusu ve tümör kitlesi sinyal intensite değerlerinden hesaplanan C/N oranında ise yüzde artış T1A SE sekansı için ortalama %58.69, yağ baskılı T1A SE sekansta %125.41 ve T1A GRE sekansta %62.06 olarak saptandı. Ayrıca uygulanan sinyal intensite ölçümlerine göre her üç sekansta elde edilen kontrast öncesi ve sonrası C/N oranlarındaki artış istatistiksel olarak anlamlı idi (paired Student t testi p

Anahtar Kelimeler:

Pankreas neoplazmları, Sinyal gürültü oranı, Mangan, Manyetik rezonans görüntüleme

Evaluation of pancreatic malign tumours with mangafodipir trisodium

Objectives: Our study aimed to assess the diagnostic capabilities of mangafodipir trisodium (Mn-DPDP)- enhanced magnetic resonance imaging for the evaluation of pancreatic malign mass. Patients and Methods: Magnetic resonance images of 17 patients (7 females, 10 males; mean age 63.2±12 years; range 36 to 80 years) suspected of pancreatic tumor by abdominal ultrasonography and computed tomography findings, were examined in terms of signal to noise (S/N) and contrast to noise (C/N) ratios before and after administration of Mn-DPDP using T1 A SE, Fat Sat T1 A SE and GRE T1 A sequences. Results: Before and after administration of Mn-DPDP, the increase in S/N ratios of normal pancreatic parenchyma were found as 22.81%, 32.88% and 20% in T1 A SE, Fat Sat T1 A SE and GRE T1 A sequences, respectively. The increase in C/N ratios obtained from signal intensity values of normal pancreatic tissue and tumor were found as 58.69%, 125.41% and 62.06% in T1 A SE, Fat Sat T1 A SE and GRE T1 A sequences, respectively. Furthermore, in all sequences, before and after contrast medium administration, the increase of C/N ratios were found statistically significant (paired Student's t test, p<0.0001). Conclusion: The differences of C/N ratio using Mn-DPDP as a contrast agent may contribute to the diagnosis of pancreatic malign masses.

Keywords:

Pancreatic Neoplasms, Signal-To-Noise Ratio, Manganese, Magnetic Resonance Imaging,

PDF

___

1) Stanley RJ, Semelka RC. Pancreas. Lee JKT, Sagel SS, Stanley RJ, Heiken JP, editors. Computed body tomography with MRI correlation. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 1998. p. 881-902.
2) Gehl HB, Urhahn R, Bohndorf K, Klever P, Hauptmann S, Lodemann KP, et al. Mn-DPDP in MR imaging of pancreatic adenocarcinoma: initial clinical experience. Radiology 1993;186:795-8.
3) Freeny PC, Traverso LW, Ryan JA. Diagnosis and staging of pancreatic adenocarcinoma with dynamic computed tomography. Am J Surg 1993;165:600-6.
4) Smedby O, Riesenfeld V, Karlson B, Jacobson G, Löfberg A, Lindgren PG, et al. Magnetic resonance angiography in the resectability assessment of suspected pancreatic tumours. Eur Radiol 1997;7:649-53.
5) Semelka RC, Simm FC, Recht MP, Deimling M, Lenz G, Laub GA. MR imaging of the pancreas at high field strength: comparison of six sequences. J Comput Assist Tomogr 1991;15:966-71.
6) Semelka RC, Kroeker MA, Shoenut JP, Kroeker R, Yaffe CS, Micflikier AB. Pancreatic disease: prospective comparison of CT, ERCP, and 1.5-T MR imaging with dynamic gadolinium enhancement and fat suppression. Radiology 1991;181:785-91.
7) Ichikawa T, Haradome H, Hachiya J, Nitatori T, Ohtomo K, Kinoshita T, et al. Pancreatic ductal adenocarcinoma: preoperative assessment with helical CT versus dynamic MR imaging. Radiology 1997;202:655-62.
8) Obuz F, Dicle O, Coker A, Sağol O, Karademir S. Pancreatic adenocarcinoma: detection and staging with dynamic MR imaging. Eur J Radiol 2001;38:146-50.
9) Rummeny E, Ehrenheim C, Gehl HB, Hamm B, Laniado M, Lodemann KP, et al. Manganese-DPDP as a hepatobiliary contrast agent in the magnetic resonance imaging of liver tumors. Results of clinical phase II trials in Germany including 141 patients. Invest Radiol 1991;26 Suppl 1:S142-5.
10) Gehl HB, Vorwerk D, Klose KC, Günther RW. Pancreatic enhancement after low-dose infusion of Mn-DPDP. Radiology 1991;180:337-9.
11) Schima W, Függer R, Schober E, Oettl C, Wamser P, Grabenwöger F, et al. Diagnosis and staging of pancreatic cancer: comparison of mangafodipir trisodiumenhanced MR imaging and contrast-enhanced helical hydro-CT. AJR Am J Roentgenol 2002;179:717-24.
12) Rieber A, Tomczak R, Nüssle K, Klaus H, Brambs HJ. MRI with mangafodipir trisodium in the detection of pancreatic tumours: comparison with helical CT. Br J Radiol 2000;73:1165-9.
13) Ramsay D, Marshall M, Song S, Zimmerman M, Edmunds S, Yusoff I, et al. Identification and staging of pancreatic tumours using computed tomography, endoscopic ultrasound and mangafodipir trisodiumenhanced magnetic resonance imaging. Australas Radiol 2004;48:154-61.
14) Boraschi P, Donati F, Gigoni R, Caramella D, Boggi U, Falaschi F, et al. Mangafodipir trisodium-enhanced MR imaging of pancreatic disease. Eur Radiol 2006;16:988-97.